Xingli Wang

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation

Yuguo Liu, L. Luan, Xingli Wang, 2015, OncoTargets and therapy.

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors

H. Mamdani, J. Baranda, D. Uprety, 2023, Cancers.

Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas

A. Hui, Xin Huang, K. Zeng, 2023, BMC Medicine.

Analysis of dose verification results for 924 intensity‐modulated radiation therapy plans

Yong Yin, Xingli Wang, Qingtao Qiu, 2018, Precision Radiation Oncology.

Oncotargets and Therapy Dovepress Dovepress

Yuguo Liu, Zhaowei Xu, Min Chen, 2022 .

Model‐informed dose selection for an investigational human epidermal growth factor receptor 2 antibody–drug conjugate FS‐1502 in patients with human epidermal growth factor receptor 2‐expressing advanced malignant solid tumours

Zhuli Wu, Xingli Wang, Yi Sun, 2023, British journal of clinical pharmacology.

HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial

Yongli Jin, Yunjiang Liu, Zhuli Wu, 2024, Nature communications.